CTI BioPharma Corp (CTIC) received FDA Fast Track Designation for Pacritinib Wednesday night and the stock is on fire this morning. Shares of the biopharma company are higher by 4% to $2.54 in early pre market trading. The Seattle, Washington – based company announced that pacritinib, an oral tyrosine kinase inhibitor drug candidate with dual […]
View the full post at: CTI BioPharma (CTIC) Receives Fast Track FDA Status